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PCardiac Resynchronization Therapy
Long-Term Prognosis After
Cardiac Resynchronization Therapy
Is Related to the Extent of Left Ventricular
Reverse Remodeling at Midterm Follow-Up
Claudia Ypenburg, MD,* Rutger J. van Bommel, MD,* C. Jan Willem Borleffs, MD,*
Gabe B. Bleeker, MD, PHD,* Eric Boersma, PHD,† Martin J. Schalij, MD, PHD,*
Jeroen J. Bax, MD, PHD*
Leiden and Rotterdam, the Netherlands
Objectives The aim of the current study was to evaluate the relation between the extent of left ventricular (LV) reverse re-
modeling and clinical/echocardiographic improvement after 6 months of cardiac resynchronization therapy
(CRT) as well as long-term outcome.
Background Despite the current selection criteria, individual response to CRT varies significantly. Furthermore, it has been
suggested that reduction in left ventricular end-systolic volume (LVESV) after CRT is related to outcome.
Methods A total of 302 CRT candidates were included. Clinical status and echocardiographic evaluation were performed
before implantation and after 6 months of CRT. Long-term follow-up included all-cause mortality and hospitaliza-
tions for heart failure.
Results Based on different extents of LV reverse remodeling, 22% of patients were classified as super-responders (de-
crease in LVESV 30%), 35% as responders (decrease in LVESV 15% to 29%), 21% as nonresponders (decrease
in LVESV 0% to 14%), and 22% negative responders (increase in LVESV). More extensive LV reverse remodeling
resulted in more clinical improvement, with a larger increase in LV function and more reduction in mitral regurgi-
tation. In addition, more LV reverse remodeling resulted in less heart failure hospitalizations and lower mortality
during long-term follow-up (22  11 months); 1- and 2-year hospitalization-free survival rates were 90% and
70% in the negative responder group compared with 98% and 96% in the super-responder group (log-rank
p value 0.001).
Conclusions The extent of LV reverse remodeling at midterm follow-up is predictive for long-term outcome in CRT
patients. (J Am Coll Cardiol 2009;53:483–90) © 2009 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.10.032(
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durrent selection criteria for cardiac resynchronization ther-
py (CRT) include severe heart failure (New York Heart
ssociation [NYHA] functional class III or IV), depressed
ystolic function (left ventricular ejection fraction [LVEF]
35%), and wide QRS complex (120 ms) (1). CRT
mproves not only clinical status (NYHA functional class,
uality of life, and exercise capacity) but also left ventricular
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008, accepted October 19, 2008.LV) function, with reverse LV remodeling, and decreases
ospitalization and mortality rates (2–7). Despite the im-
ressive results of CRT in the large clinical trials, response
o CRT varies significantly among individuals; some pa-
ients exhibit a significant improvement in clinical status
ith extensive LV reverse remodeling and almost normal-
zation of LV function, whereas other patients show dete-
ioration of both clinical and functional parameters despite
RT. Furthermore, preliminary results demonstrated a
elation between the magnitude of LV reverse remodeling
nd long-term survival benefit after CRT (8).
Therefore, the aims of the current study were: 1) to
valuate the relation between the extent of LV reverse
emodeling and the improvement in clinical and echocar-
iographic parameters after 6 months of CRT; and 2) to
valuate the relation between the extent of LV reverse remod-
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Extent of LV Reverse Remodeling After CRT February 10, 2009:483–90eling and long-term outcome. To
permit subgroup analysis, the pa-
tients were arbitrarily divided into
4 groups, based on the extent of
LV reverse remodeling after 6
months of CRT.
Methods
Patients and study protocol.
The study population consisted
of 302 consecutive heart failure
patients who were scheduled for
CRT device implantation. The
selection criteria for CRT in-
cluded advanced heart failure
(NYHA functional class III or
IV), LVEF 35%, and wide
RS complex (1). Patients with a recent myocardial infarc-
ion (3 months) or decompensated heart failure were
xcluded. Etiology was considered ischemic in the presence
f significant coronary artery disease (50% stenosis in 1 or
ore of the major epicardial coronary arteries) and/or a
istory of myocardial infarction or prior revascularization.
The study protocol included baseline 2-dimensional
chocardiography to measure LVEF and LV volumes as
ell as tissue Doppler imaging to assess LV dyssynchrony.
linical evaluation included assessment of NYHA func-
ional class, quality of life (using the Minnesota Living with
eart Failure questionnaire) (9), and evaluation of exercise
apacity using the 6-min walking test (10). At 6 months
ollow-up, clinical status, LV volumes, and LVEF were
eassessed. During long-term follow-up after implantation,
urvival and cardiac transplantation as well as hospitaliza-
ion for decompensated heart failure were reported.
efinition of response. Patients who died, were hospital-
zed, and/or functionally deteriorated before the 6-month
ollow-up were discarded from further analysis. The re-
aining group consisted of clinically improved and un-
hanged patients at 6 months, and was divided into sub-
roups based on the reduction in left ventricular end-systolic
olume (LVESV) after 6 months of CRT. The specific
ubgroups were negative responders: patients with an increase
n LVESV; nonresponders: patients with a decrease in
VESV ranging from 0% to 14%; responders: patients with a
ecrease in LVESV ranging from 15% to 29%; and super-
esponders: patients with a decrease in LVESV 30%.
chocardiographic evaluation. Echocardiographic images
ere obtained with a 3.5-MHz transducer in the left lateral
ecubitus position using a commercially available system
Vivid Seven, General Electric-Vingmed, Milwaukee, Wis-
onsin). Standard 2-dimensional and color Doppler data,
riggered to the QRS complex, were saved in cine-loop format
or offline analysis (EchoPAC version 6.0.1, GE Medical
ystems, Horten, Norway). Left ventricular end-diastolic vol-
Abbreviations
and Acronyms
CRT  cardiac
resynchronization therapy
LBBB  left bundle branch
block
LV  left ventricle/
ventricular
LVEDV  left ventricular
end-diastolic volume
LVEF  left ventricular
ejection fraction
LVESV  left ventricular
end-systolic volume
NYHA  New York Heart
Associationme (LVEDV) and LVESV were derived, and LVEF was aalculated from the conventional apical 2- and 4-chamber
mages, using the biplane Simpson’s technique (11).
The severity of mitral regurgitation was graded semi-
uantitatively from color-flow Doppler images using the
pical 4-chamber views. Mitral regurgitation was graded on
4-point scale: none, mild (jet area/left atrial area 20%),
oderate (jet area/left atrial area 20% to 45%), and severe
jet area/left atrial area 45%) (12).
For tissue Doppler imaging, color-coded images of the 4-
nd 2-chamber apical views of 3 consecutive heart beats
ere stored for offline analysis. Data were analyzed using
ommercially available software (EchoPAC version 6.0.1,
E Medical Systems). To determine LV dyssynchrony, the
ample volume was placed in the LV basal parts of the
nterior, inferior, basal, and lateral wall, and per region, the
ime interval between the onset of QRS complex and the
eak systolic velocity was derived. LV dyssynchrony was
efined as the maximal delay between peak systolic velocities
mong the 4 LV walls. Based on previous data, a cutoff value
f 65 ms was used as a marker of LV dyssynchrony (13).
ong-term follow-up. Chart review, device interrogation,
nd telephone contact were assessed during long-term
ollow-up after device implantation. Events were defined as
eath (due to heart failure, other cardiac cause, or noncar-
iac cause) or cardiac transplantation, and hospitalization
or decompensated heart failure. Since the subgroups were
ormed after 6 months of CRT, the composite of death,
ardiac transplantation, and hospitalizations for heart failure
ccurring after the 6-month follow-up evaluation was the
rimary end point of the study.
evice implantation. A coronary sinus venogram was
btained using balloon catheter, followed by the insertion of
he LV pacing lead. An 8-F guiding catheter was used to
osition the LV lead (Easytrak 4512-80, Guidant Corpo-
ation, St. Paul, Minnesota; or Attain-SD 4189, Medtronic
nc., Minneapolis, Minnesota) in the coronary sinus. The
referred position was a lateral or posterolateral vein (14).
he right atrial and ventricular leads were positioned
onventionally. All leads were connected to a dual-chamber
iventricular implantable cardioverter-defibrillator (Contak
enewal II or H195, Guidant Corporation; or Insync III or
nsync Sentry, Medtronic Inc.).
tatistical analysis. Continuous variables are expressed as
ean  SD. Categorical data are summarized as frequen-
ies and percentages. Differences in baseline characteristics
etween the 4 different subgroups were analyzed using
-way analysis of variance (continuous variables) and chi-
quare (dichotomous variables) as appropriate. The paired
tudent t test was used to compare continuous data within
he subgroups during follow-up. The McNemar test was
sed to compare NYHA functional class and severity of
itral regurgitation during follow-up within the different
ubgroups. Event and survival curves were determined
ccording to the Kaplan-Meier method, with comparisons
f cumulative event rates by the log-rank test. For all tests,
p value 0.05 was considered statistically significant.
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February 10, 2009:483–90 Extent of LV Reverse Remodeling After CRTesults
atients. The study population consisted of 302 consecu-
ive patients (253 men, mean age 66  10 years). All
atients had advanced heart failure symptoms with most
atients (94%) in NYHA functional class III. Underlying
tiology of cardiomyopathy was ischemic in 58% of patients
nd idiopathic in 42%. Patients had severely depressed LV
unction (mean LVEF 25 8%) with extensive LV dilation
mean LVEDV 227  78 ml and mean LVESV 172  68
l). Mean extent of LV dyssynchrony was 78  46 ms.
edication included diuretics in 90%, angiotensin-
onverting enzyme inhibitors in 90%, beta-blockers in 74%,
nd spironolactone in 53% of patients. Device and lead
mplantation was successful in all patients without major
rocedure-related complications.
ollow-up after CRT. Sixteen patients were removed
rom further analysis at 6 months follow-up; 10 died, 2
eteriorated in functional class, and 4 were hospitalized for
Figure 1 Extent of LV Reverse
Remodeling After 6 Months of CRT
Distribution of patients according to extent of left ventricular (LV) reverse
remodeling after 6 months of cardiac resynchronization therapy (CRT).
LVESV  left ventricular end-systolic volume.
aseline Characteristics of the Different Subgroups (Definedccording to the Extent of LV Revers Remodeling Aft r 6 Months
Table 1 Baseline Characteristics of the Different Subgroups (DAccording to the Extent of LV Reverse Remodeling Aft
Variable NEG (n  63) NON (n 
Age (yrs) 65 10 65 12
Sex (M/F) 54/9 51/9
NYHA functional class (III/IV) 55/8 57/3
Ischemic etiology 47 (74%) 41 (68%
QRS duration (ms) 142 33 156 30
LBBB 32 (51%) 46 (77%
SR/AF/paced 50/9/4 47/7/6
LVEF (%) 26 8 24 8
LVEDV (ml) 215 75 233 78
LVESV (ml) 160 61 181 78
MR moderate-to-severe 12 (19%) 12 (20%
LV dyssynchrony (ms) 50 36 58 35
F atrial fibrillation; CRT cardiac resynchronization therapy; LBBB left bundle branch block; L
VESV left ventricular end-systolic volume; MRmitral regurgitation; NEG negative responders; NON
UPER  super-responders.ecompensated heart failure before the 6-month follow-up.
f the remaining 286 patients, 164 patients (57%) showed
n improvement of 1 NYHA functional class and 34
atients (12%) showed an improvement of 2 NYHA func-
ional classes, whereas 88 patients (31%) remained un-
hanged (p  0.001 vs. baseline) at 6 months follow-up. In
ddition, both quality of life and exercise capacity improved
t 6 months (respectively from 36  19 to 25  20, and
alking distance from 321  107 m to 395  111 m, both
 0.001). Furthermore, LVEF improved modestly (from
5  8% to 32  10%, p  0.001), with a reduction in LV
olumes; LVEDV decreased from 226 78 ml to 200 77
l and LVESV from 170  67 ml to 139  67 ml (both
 0.001) at 6 months. In addition, 107 patients (37%)
howed a reduction in mitral regurgitation of at least 1
rade, 152 (53%) remained unchanged, and 27 (10%)
howed worsening of mitral regurgitation after 6 months of
RT (p  0.001).
During follow-up (22  11 months, range 6 to 53
onths), 37 patients died (13%). Cause of death was
ecompensated heart failure in 26, other cardiac cause in 7,
nd noncardiac cause in 4 patients. One patient underwent
eart transplantation. In addition, hospitalizations for de-
ompensated heart failure were noted in 21 patients (7%).
ubgroup analysis according to extent of LV reverse
emodeling after 6 months of CRT. The extent of LV
everse remodeling after 6 months varied among patients,
anging from an increase in LVESV of 38% and a decrease
n LVESV of 78%, with a mean reduction of 18  22%.
ixty-three patients (22%) showed deterioration in LVESV
fter 6 months of CRT and were classified as negative
esponders (for definitions see Methods section). Further-
ore, 60 patients (21%) showed LV reverse remodeling of
% to 14% and were classified as nonresponders. LV reverse
emodeling of 15% to 29% was noted in 100, and these
atients were classified as responders (35%). In 63 patients
22%), extensive LV reverse remodeling30% was reported,
RT)
d
Months of CRT)
RESP (n  100) SUPER (n  63) p Value
66 11 67 9 0.8
85/15 48/15 0.4
96/4 63/0 0.04
51 (51%) 25 (40%) 0.001
163 28 161 33 0.001
78 (78%) 49 (78%) 0.001
75/8/17 49/5/9 0.4
26 8 25 8 0.2
224 73 231 78 0.6
168 63 175 69 0.3
11 (11%) 9 (14%) 0.001
93 40 101 45 0.001
ventricular; LVEDV left ventricular end-diastolic volume; LVEF left ventricular ejection fraction;of C
efine
er 6
60)
)
)
)
V left
 nonresponders; NYHA New York Heart Association; RESP responders; SR sinus rhythm;
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Extent of LV Reverse Remodeling After CRT February 10, 2009:483–90nd these were classified as super-responders (Fig. 1). Baseline
haracteristics between the 4 subgroups were comparable,
xcept for less severe heart failure symptoms (lower NYHA
unctional class), more often nonischemic cardiomyopathy,
onger QRS duration, more often left bundle branch block
LBBB) configuration, and more extensive LV dyssyn-
hrony in super-responders (Table 1).
esponse to CRT versus extent of LV reverse remodel-
ng. Mean NYHA functional class improved significantly
n all groups at 6 months after CRT; in negative responders
rom 3.1  0.3 to 2.9  0.5, in nonresponders from 3.1 
.2 to 2.6  0.5, in responders from 3.0  0.2 to 2.0  0.4,
nd in super-responders from 3.0 0.0 to 1.7 0.5 (for all,
 0.001). Individual changes within each subgroup are
resented in Figure 2.
As demonstrated in Figure 3 (panel A), super-responders
howed greater improvement in quality-of-life score (17
3) as compared with the other subgroups (8 15, 13
8, and 14  16, respectively, for negative responders,
onresponders, and responders, p  0.024). In addition, a
rend was noted for larger improvement in walking distance
Fig. 3B) in patients with more extensive LV reverse
A Negative-responders
NYHA Follow-upBaseline
I 0 0
II 0
55
8
10
49
4
10
45
4
4
III
IV
3.1±0.3 2.9±0.5      P<0.001
C Responders
NYHA Follow-upBaseline
I 0
0
96
4
8
87
5
0
84
4
8
3
II
III
1
IV
3.0±0.2 2.0±0.4      P<0.001
Figure 2 Improvement in NYHA Functional Class After 6 Month
Changes in New York Heart Association (NYHA) functional class after 6 months ofemodeling. iRegarding echocardiographic parameters, negative respond-
rs showed no improvement in LVEF after 6 months of CRT
from 26  8% to 26  8%, p  NS), whereas the other 3
esponse groups showed significant improvement in LVEF;
onresponders showed a mean improvement of 5  5% in
VEF, responders of 8  7%, and the greatest improvement
as observed in super-responders (15  9%, p  0.001) (Fig.
C). Also, super-responders showed greatest reduction in
VEDV after CRT (Fig. 3D). Reduction in mitral regurgita-
ion was more pronounced in patients with more LV reverse
emodeling; 13%, 22%, 48%, and 62% of negative responders,
onresponders, responders, and super-responders, respectively,
mproved at least 1 grade in mitral regurgitation (p  0.001).
ong-term follow-up after 6 months of CRT according
o extent of LV reverse remodeling. Mortality rates de-
reased in parallel to the extent of LV reverse remodeling,
ith only 1 death in the super-responder group (p  0.001)
Table 2). One-year survival rates were 92% in the negative-
esponder group, 95% in the nonresponder group, 97% in
he responder group, and 100% in the super-responder
roup, respectively (log-rank p  0.001) (Fig. 4A). The
ame trend was noted for the number of patients hospital-
Non-responders
YHA Follow-upBaseline
I 0 0
II 0
57
3
24
35
1
24
33III
1
2
IV
3.1±0.2 2.6±0.5      P<0.001
Super-responders
YHA Follow-upBaseline
I 0
0
63
23
39
1
II
1
23
39
III
0 0IV
3.0±0.0 1.7±0.5      P<0.001
CRT
c resynchronization therapy (CRT) according to the different response groups.B
N
D
N
s of
cardiazed for decompensated heart failure (Fig. 4B).
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February 10, 2009:483–90 Extent of LV Reverse Remodeling After CRTIn addition, 1- and 2-year hospitalization-free survival
ates were, respectively, 90% and 70% in the negative-
esponder group, 93% and 84% in the nonresponder group,
7% and 90% in the responder group, and 98% and 96% in
he super-responder group (log-rank p  0.001) (Fig. 4C).
eparate comparisons revealed significant differences in
ospitalization-free survival between super-responders, neg-
tive responders (p  0.001 vs. super-responders), and
onresponders (p  0.001 vs. super-responders), and a
rend for better outcome when compared with responders to
RT (p  0.06 vs. responders).
iscussion
he findings in the current study can be summarized as
ollows: 1) the extent of reverse LV remodeling varies
ignificantly among patients undergoing CRT, and 22% can
NEG NON RESP SUPER
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Figure 3 Clinical and Echocardiographic Improvement After 6 M
Improvement in clinical (A and B) and echocardiographic (C and D) parameters at
defined by an increase in left ventricular end-systolic volume, nonresponders (NON
(15% to 29%), and super-responders (SUPER) a high decrease (30%) in left vent
tion therapy.
vents During Long-Term Follow-Up According to the Extent of LV R
Table 2 Events During Long-Term Follow-Up According to the E
Variable NEG (n  63) NON
Follow-up (months) 21  10 21
Death 18 (29%) 10
Hospitalizations for HF 11 (17%) 3
Death, HTX, and hospitalizations for HF 23 (37%) 13F  heart failure; HTX  heart transplantation; other abbreviations as in Table 1.e considered super-responders; 2) more extensive LV
everse remodeling was related to greater clinical and func-
ional improvement after 6 months of CRT; and 3) more
V reverse remodeling resulted in better survival and less
ospitalization for decompensated heart failure after 6
onths of CRT.
ifferences in magnitude of response to CRT—previous
tudies. At present, only 1 study reported on “super-
esponse” after CRT (15,16). Blanc et al. (15) investigated
9 patients with nonischemic dilated cardiomyopathy,
BBB, and mean LVEF of 21%. After 12 months of CRT,
patients (17%) exhibited normalization in LVEF (50%)
ssociated with clinical improvement to NYHA functional
lass I to II; these patients were defined as “super-
esponders.” A subsequent study in 84 CRT candidates
with ischemic and nonischemic cardiomyopathy) reported
NEG NON RESP SUPER
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s of CRT
nths follow-up in the different response groups; negative responders (NEG) were
termediate decrease (0% to 14%), responders (RESP) a moderate decrease
end-systolic volume after 6 months of follow-up. CRT  cardiac resynchroniza-
se Remodeling After CRT
of LV Reverse Remodeling After CRT
0) RESP (n  100) SUPER (n  63) p Value
22  12 25  10 0.1
8 (8%) 1 (2%) 0.001
6 (6%) 1 (2%) 0.05
12 (12%) 2 (3%) 0.001B
onth
6 mo
) an in
ricularever
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Extent of LV Reverse Remodeling After CRT February 10, 2009:483–90n incidence of super-responders of 13% (16). Super-
esponders showed an increase in LVEF from 25  8% to
0  6% (p  0.001), whereas the remaining patients
howed only a modest improvement in LVEF (from 21 
% to 25  10%, p  0.004).
However, data on the magnitude of LVESV changes
fter CRT are lacking. Reverse remodeling may be more
mportant than the increase in LVEF, since reduction in
VESV appeared to be the best predictor for long-term
utcome after CRT (8).
Also of interest are the baseline characteristics of
uper-responders. In the present study, super-responders
ore frequently had nonischemic etiology of heart fail-
re, longer QRS duration, more often LBBB configura-
ion, less severe mitral regurgitation, and more extensive
V dyssynchrony (Table 2). Similarly, Castellant et al.
16) suggested that super-response only occurred after
RT in nonischemic patients with LBBB. The study by
lanc et al. (15) reported no differences in baseline
haracteristics between the super-responders and the
emaining patients; however, this particular study in-
luded only nonischemic patients with LBBB. In addi-
ion, various studies suggested a relationship between LV
everse remodeling after CRT and etiology (17–19).
hese differences in baseline characteristics help to vali-
ate the current patient selection criteria that include a
ider QRS complex, particularly with LBBB configura-
ion. Furthermore, patients with more extensive LV
amage from ischemic heart disease tend to respond less
han patients with nonischemic cardiomyopathy. Addi-
ionally, from several studies it has become clear that LV
yssynchrony is important for response to CRT; in the
urrent study, patients with extensive LV dyssynchrony
ad a high likelihood of response, whereas patients
ithout LV dyssynchrony did not respond to CRT
13,20).
xtent of LV reverse remodeling in CRT—impact on
rognosis. Besides clinical end points such as NYHA
unctional class, quality-of-life score, and 6-min walking
istance, echocardiographic end points have been used in
eart failure trials (21). Importantly, reversal of LV remod-
ling in heart failure patients by either pharmacological or
nterventional therapies is proposed as a surrogate for
mproved outcome (22).
For instance, in the SOLVD (Studies of Left Ventricular
ysfunction) trial, patients who were randomized to enala-
ril showed a decrease in LVESV after 1-year follow-up
from 106  42 ml/m2 to 93  37 ml/m2, p  0.01)
hereas patients treated with placebo showed an increase
n LVESV at 1-year follow-up (from 103  24 ml/m2 to
16  24 ml/m2, p  0.08) (23,24). Since enalapril usage
as associated with a 16% reduction in mortality during
3 months of follow-up, it is reasonable to conclude that
he LV reverse remodeling effect is associated with
avorable outcome. Similar findings on the remodeling6 12 18 24 30 36
Follow -up afte r CR T (m onths)
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100 % Log-rank p-value <0.001
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Figure 4 Long-Term Outcome After CRT
According to the Extent in LV Reverse Remodeling
Event curves for all-cause mortality (A), hospitalizations for heart failure
(B), and primary combined end point of death and hospitalizations for heart
failure (C) for the different CRT response groups. INTER  intermediate
responder; LV  left ventricular; other abbreviations as in Figure 3.rocess have been reported after the use of carvedilol in
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February 10, 2009:483–90 Extent of LV Reverse Remodeling After CRTatients with chronic LV dysfunction late after myocar-
ial infarction (25,26) as well as metoprolol in patients
ith mild-to-moderate heart failure and chronic LV
ysfunction (27).
These data from pharmacological heart failure trials
mphasize the importance of LV reverse remodeling and,
onsequently, long-term prognosis. Currently, only 1
tudy related the extent of reverse remodeling after CRT
o outcome: Yu et al. (8) evaluated 141 patients and
elated the extent of reduction in LVESV to long-term
linical outcome (mean follow-up 695  491 days).
eceiver-operating characteristic curve analysis showed
hat a reduction of 10% in LVESV had a sensitivity and
pecificity of 70% in predicting all-cause mortality. In
ddition, the change in LVESV was the best predictor for
ong-term outcome, whereas clinical parameters showed
o predictive value.
In the present study, 286 patients were categorized
ccording to reduction in LVESV after 6 months of
RT; 22% were classified as super-responders (decrease
n LVESV 30%), 35% as responders (decrease in
VESV 15% to 29%), 21% as nonresponders (decrease in
VESV 0% to 14%), and 22% negative responders
increase in LVESV). Expanding the results of Yu et al.
8), an inverse relation between the extent of LV reverse
emodeling and outcome was noted. negative responders
ad a high event rate (37%) for combined death and heart
ailure hospitalizations, as compared with 22% in nonre-
ponders, 12% in responders, and only 3% in super-
esponders. Importantly, super-responders exhibited a
uperior 1- and 2-year hospitalization-free survival of
8% and 96%, respectively.
onclusions
he extent of LV reverse remodeling after CRT varies
ignificantly among individuals, with 22% considered super-
esponders to CRT. Importantly, the extent of reverse
emodeling after 6 months is related to clinical improve-
ent and survival during long-term follow-up.
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